

Adrenocorticotrophic Hormone

I. Drugs

A. ACTH >

II. Activity: _____

III. Adverse Effects:

A. _____

B. _____

C. Weight gain

Growth Hormone (Somatostatin)

I. Drugs

A. Growth Hormone

II. Indications

A. _____

B. _____

III. Activity: _____

A. _____

B. Stimulates other growth factors

1. _____

2. _____

C. _____

IV. Adverse Effects

A. Arthralgias/Myalgias

B. Diabetes

Somatostatin Analogues

I. Drugs

A. _____ > _____

B. _____ > _____

II. Activity: Suppresses:

A. _____

B. _____

C. _____

D. _____

E. _____

III. Adverse Effects: GI Disturbances

GNRH Analogues

I. Drugs

A. _____

B. _____

C. _____

D. _____

II. Indications

A. _____

B. _____

C. _____

D. Sex Hormone-Related Conditions

III. Activity: _____ → ↓ _____

IV. Adverse Effects:

A. _____

B. _____

C. _____

Ergot Dopamine Receptor Agonists

I. Drugs

A. _____ > _____,

B. _____ > _____

II. Activity: _____

III. Adverse Effects:

A. Bromocriptine > Sedation, hypotension,
_____ and _____

B. Cabergoline > _____

Oxytocin

I. Drugs

A. Oxytocin

II. Indications:

A. _____

B. _____

III. Activity: _____

IV. Adverse Effects:

A. _____

B. HTN

C. _____

Antidiuretic Hormone

I. Drugs

A. _____

B. _____

II. Indications

A. _____ (_____)

B. _____ (_____)

C. _____

III. Activity:

A. ___ Receptors: _____

B. ___ Receptors: _____

IV. Adverse Effects: _____

Thyroid Hormone

I. Drugs

A. _____

B. _____

II. Indication: _____

III. Activity: _____

IV. Adverse Effects

A. _____

B. _____

C. Heat intolerance

D. Nervousness

Antithyroid Drugs

I. Drugs

A. _____ > _____

B. _____ > _____

C. Iodide > _____, _____,
_____, hyperthyroidism

II. Activity:

A. Thioamide: Inhibits _____

B. Iodide:

1. _____

2. _____

3. _____

III. Adverse Effects

A. Thioamides: _____,

_____, _____

B. Iodide: Metallic mouth taste, mouth sores

Insulin I. Drugs A. _____ > Short-acting B. _____ > Rapid-acting C. _____ > Rapid-acting D. _____ > Rapid-acting E. _____ > Intermediate-acting F. _____ > Long-acting G. _____ > Long-acting H. _____ > Long-acting II. Indications: Diabetes III. Activity: _____, _____ IV. Adverse Effects: A. _____ B. _____ Amylin Analogs I. Drugs A. _____ > Adjunct to insulin in DM B. Activity: Amylin effects 1. _____ 2. _____ 3. _____ C. Adverse Effects: 1. _____ 2. _____ GLP-1 Agonists I. Drugs A. _____ > TIIDM B. _____ > TIIDM C. _____ – TIIDM, _____ D. _____ – TIIDM, _____ II. Activity: _____ A. ↑ _____ secretion B. Delay _____ C. ↑ _____ D. ↓ _____ E. ↑ _____ III. Adverse Effects: A. _____ B. N/V/D	Sulfonylureas I. Drugs A. _____ B. _____ C. _____ II. Indications: TIIDM III. Activity: _____ A. _____ → Depolarization of beta cells → Ca^{2+} influx → insulin secretion B. Increases _____ C. Decreases _____ IV. Adverse Effects: A. _____ B. _____ Glinides I. Drugs A. _____ B. _____ II. Indications: TIIDM III. Activity: _____ A. _____ → Depolarization of beta cells → Ca^{2+} influx → insulin secretion IV. Adverse Effects: A. _____ B. _____ Biguanides I. Drugs A. _____ II. Indications A. TIIDM B. _____ III. Activity: A. Decreases _____ B. Increased _____ C. Decreased _____ IV. Adverse Effects: A. _____ B. Contraindicated in _____ C. _____	Thiazolidinediones I. Drugs A. _____ B. _____ II. Indications: TIIDM III. Activity: _____ A. Activates _____, ↑ transcription of insulin responsive genes IV. Adverse Effects: A. _____ B. _____ C. _____ Alpha Glucosidase Inhibitors I. Drugs A. _____ B. _____ II. Indications: TIIDM III. Activity: _____ A. Decreases _____ IV. Adverse Effects: A. Abdominal cramps, diarrhea, flatulence Dipeptidyl Peptidase-4 Inhibitors I. Drugs A. _____ B. _____ C. _____ D. _____ II. Indications: TIIDM III. Activity: _____ A. Promotes _____ activity B. ↑ _____ and ↓ _____ release IV. Adverse Effects: A. _____ B. Nasopharyngitis
--	---	---

Sodium-Glucose Cotransporter 2 Inhibitors

I. Drugs

- A. _____
 B. _____
 C. _____

II. Indications: TIIDM

III. Activity: _____

- A. ↓ _____ reabsorption
 B. ↓ _____ reabsorption

IV. Adverse Effects:

- A. _____
 B. _____

Estrogens

I. Drugs

- A. _____
 B. _____
 C. _____
 D. _____

II. Indications

- A. _____
 (_____, _____)
 B. _____
 C. _____

III. Activity: _____

IV. Adverse Effects:

- A. _____
 B. Nausea
 C. _____

Selective Estrogen Receptor Modifiers

I. Drugs

- A. _____
 1. Indication: _____
 2. Activity: _____
 3. Adverse Effects: _____
 B. _____ > _____
 C. _____ > Dyspareunia
 D. _____ > _____
 E. _____ > _____
 F. _____ > _____

II. Activity:

- A. _____ (Breast)
 B. _____ (Bone) (_____, _____)

III. Adverse Effects: Nausea, hot flashes

Progestogens

I. Drugs

- A. _____
 B. _____
 C. _____
 D. _____
 E. _____
 F. _____
 G. _____
 H. _____
 I. _____
 J. _____
 K. _____

II. Indications:

- A. _____
 B. _____
 C. Activity: _____

III. Adverse Effects:

- A. Headache
 B. Weight Gain
 C. Acne
 D. Depression

Selective Progesterone Receptor Modifiers

I. Drugs

- A. _____ > _____

II. Action

- A. _____ @ _____
 receptors

III. Adverse Effects

- A. Prolonged menstruation
 B. Nausea/Headaches

Progesterone Antagonists

I. Drugs

- A. _____ > _____

II. Action:

- III. Adverse Effects
 A. _____
 B. _____

Androgens

I. Drugs

- A. _____ > _____, _____
 B. _____ > _____, wasting
 C. _____ > _____, wasting
 D. _____ > _____, wasting
 E. _____ > _____, wasting
 F. _____ > _____, wasting

II. Activity:

- A. _____
 B. _____ - _____

III. Adverse Effects: Excess androgen effects

5-Alpha Reductase Inhibitors

V. Drugs

- A. _____ > _____
 B. _____ > _____

VI. Activity: _____, ↓ _____ levels

VII. Adverse Effects

- A. _____
 B. Decreased _____
 C. _____
 D. _____

Competitive Androgen Inhibitors

I. Drugs

- A. _____
- B. _____
- C. _____

II. Indications: _____

III. Activity: _____

IV. Adverse Effects:

- A. _____
- B. _____

Glucocorticoids

I. Drugs

- A. _____
- B. _____
- C. _____
- D. _____
- E. _____
- F. _____
- G. _____
- H. _____
- I. _____
- J. _____
- K. _____
- L. _____
- M. _____

II. Indications

- A. Many indications
- B. _____
- C. _____
- D. _____
- E. _____

III. Activity:

- A. ↑ _____
- B. ↑ _____
- C. Anti-inflammatory
 - 1. Stabilizes _____
 - 2. Inhibition of _____
- D. Immunosuppressive
 - 1. ↓ _____
- E. Inhibits ___ and ___ release

IV. Adverse Effects:

- A. _____
- B. _____
- C. _____
- D. _____
- E. _____ → _____

Mineralocorticoids

I. Drugs

- A. _____

II. Indications: _____

III. Activity: Mimics _____. Some _____ effects

IV. Adverse Effects:

- A. _____
- B. _____

Obesity Drugs

I. Drugs

- A. _____
- B. _____ >

1. Activity: _____ inhibitor. Stimulant effects.

2. Adverse Effects: _____, _____

C. _____

1. Activity: _____ & _____ reuptake inhibitor. Stimulant effects.

2. Adverse Effects: _____, _____

D. _____

1. Activity: _____, ↓ _____

2. Adverse Effects: _____ deficiency, diarrhea etc., _____

E. _____

1. Activity: _____ agonist. Activates _____ receptors, decreasing appetite

2. Adverse Effects: _____, _____ syndrome